Ciprofloxacin i.v. Defining Its Role in Serious Infections
On the occasion of a symposium in Salzburg, an international team of clinicians and pharmacologists presented recent results in profile efficacy, safety and therapeutic use of the antibiotic substance Ciprofloxacin. Of special interest for clinicians will
- PDF / 26,438,190 Bytes
- 151 Pages / 439 x 666 pts Page_size
- 49 Downloads / 176 Views
c. Garrard (Ed.)
Ciprofloxacin i. v. Defining Its Role in Serious Infections International Symposium, Salzburg, September 1993
Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest
DR. CHRISTOPHER GARRARD
John Radcliffe Hospital Intensive Care Director Oxford OX3 9 DU, United Kingdom
ISBN-13: 978-3-642-79100-0 e-ISBN -13: 978-3 -642-79098-0 DOl: 10.1007/978-3-642-79098-0
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concemed, specifically the rights of translation, reprintmg, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of thiS pubhcation or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its current version and a copyright fee must always be paid. Violations fall under the prosecutIOn act of the German Copyright Law. © Spnnger-Verlag Berlin Heidelberg 1994 Softcover reprint of the hardcover I st edition 1994 The use of registered names, trademarks, etc in this publication does not imply, even i~ the absence of a specific statement, that such names are exempt from the relevant protective laws and regulation and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Typesetting: Storch GmbH, Wiesentheid 23/3130 - 5 4 3 2 I 0 - Printed on acid-free paper
Preface
The fluoroquinolone ciprofloxacin has been used in a wide range of bacterial infections. This antibacterial agent has a broad spectrum of activity and is associated with relatively few side effects. Both oral and intravenous administration can achieve effective levels at the focus of infection. In addition to demonstrable efficacy against a wide range of micro-organisms, ciprofloxacin is endowed with other pharmacodynamic characteristics. Because of its favourable pharmacokinetics and pharmacodynamics ciprofloxacin proved to be efficacious following oral doses ranging from 250 to 750 mg bid or i.v. doses of 100-200 mg bid against "less severe" infections. However, infections in immunocompromised patients and other severe infections might necessitate i.v. doses of 400 mg bid-tid. A symposium was held in Salzburg, Austria in September 1993 to address the issue of efficacy and safety of ciprofloxacin 400 mg i. v. in the treatment of severe infections. In addition, in vitro data and results generated in experimental animals were presented, demonstrating new pharmacodynamic characteristics of ciprofloxacin, probably contributing to its clinical efficacy: It is tempting to speculate that effects such as bactericidal efficacy against extremely slowly growing bacteria, pronounced postantibiotic effect and endotoxin binding capacity might be of clinical relevance. In clinical studies it could
